论文部分内容阅读
目的探讨维生素D3对2型糖尿病(T2DM)患者糖代谢和体内相关炎症因子水平的影响。方法选择无急性并发症的T2DM患者85例。按性别、年龄因素随机分为基础治疗组(对照组)和基础治疗加维生素D3组(维生素D组)。对照组采用基础药物将空腹血糖(FPG)控制在7.0 mmol/L以下,将餐后2 h血糖(2 hPG)控制在10.0 mmol/L以下。维生素D组在对照组基础上口服维生素D31 000 IU/d。疗程12周。在疗程结束后的次日取空腹血清,ELISA法测定血清中炎症因子白介素-6(IL-6)和肿瘤坏死因子-α(TNF-α)水平。同时测定FPG、2 hPG、超敏C反应蛋白(hs-CRP)和糖化血红蛋白(HbA1c)。结果经过12周的治疗,维生素D组患者的FPG、2 hPG和HbA1c值与对照组比较,差异均无统计学意义(均P>0.05);但维生素D组患者体内的hs-CRP、TNF-α和IL-6水平均明显低于对照组(均P<0.05)。结论维生素D3降低了T2DM患者体内的炎症状态。
Objective To investigate the effects of vitamin D3 on glucose metabolism and the level of inflammatory cytokines in patients with type 2 diabetes mellitus (T2DM). Methods Eighty-five patients with T2DM without acute complications were selected. According to sex and age, they were randomly divided into basic treatment group (control group) and basic treatment plus vitamin D3 group (vitamin D group). In the control group, the fasting blood glucose (FPG) was controlled below 7.0 mmol / L and the 2 h postprandial blood glucose (2 hPG) below 10.0 mmol / L using basic drugs. Vitamin D group in the control group based on oral vitamin D31 000 IU / d. Treatment for 12 weeks. Fasting serum was taken on the next day after the end of treatment, and the levels of interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) in serum were measured by ELISA. Meanwhile, FPG, 2 hPG, hs-CRP and HbA1c were determined. Results After 12 weeks of treatment, the levels of FPG, 2 hPG and HbA1c in vitamin D group were not significantly different from those in control group (all P> 0.05). However, the levels of hs-CRP and TNF- α and IL-6 levels were significantly lower than the control group (P <0.05). Conclusion Vitamin D3 reduces the inflammatory status in T2DM patients.